A new dual-action medication to cause double-trouble for Tuberculosis

Type of Opportunity: Licensing / Collaboration Opportunity

Keywords: Mycobacterium tuberculosis | drug resistance | antibiotics | subsequent delivery

Source: Academic Medical Center (AMC) -  Medical Biology

Tuberculosis is once again a threat to the world, especially due to the multi-drug resistant species that have infected around 500.000 humans world-wide in 2015 alone. Treatment options for these patients are limited and expensive, and more dramatically, in some cases completely absent.
Using high resolution microscopy techniques we discovered that upon antibiotic treatment the DNA of Mycobacterium tuberculosis condenses into a single clump. Using a combination of antibiotics and inhibitors of DNA binding proteins, we have been able to disrupt the recovery after DNA condensation. By developing an oral formulation that sequentially releases the antibiotic and inhibitors, we are aiming to develop a treatment for drug-resistance bacteria.

Contact: IXA-AMC | Marc Roelofs | +31 20 566 8021 | m.roelofs@ixa.nl

Click for more details on this licensing opportunity